Phase 1Recruiting
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
- Sponsor
- Marcela V. Maus, M.D.,Ph.D. (Academic or other)
- Enrolment
- 24 planned
- Conditions
- Non-hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma (PMBCL); High-grade B-cell Lymphoma; Grade 3b Follicular Lymphoma; Mantle Cell Lymphoma
- Interventions
- CD79b-19 CAR T cells; Cyclophosphamide; Fludarabine
- Ages
- adults, older adults
- Registry
- NCT06026319
Full record on ClinicalTrials.gov
From the registry
This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Primary outcomes
- Incidence of adverse events (AEs)
- Incidence of Dose Limiting Toxicity (DLT)
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered